Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA.
Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02129-20.
Oxfendazole is a potent veterinary benzimidazole anthelmintic under transition to humans for the treatment of multiple parasitic infectious diseases. The first-in-human study evaluating the disposition of oxfendazole and its metabolites in healthy adults following single ascending oral doses from 0.5 to 60 mg/kg of body weight shows that oxfendazole pharmacokinetics is substantially nonlinear, which complicates correlating oxfendazole dose to exposure. To quantitatively capture the relation between oxfendazole dose and exposure, a population pharmacokinetic model for oxfendazole and its metabolites, oxfendazole sulfone and fenbendazole, in humans was developed using a nonlinear mixed-effect modeling approach. Our final model incorporated mechanistic characterization of dose-limited bioavailability as well as different oxfendazole metabolic processes and provided insight into the significance of presystemic metabolism in oxfendazole and metabolite disposition. Oxfendazole clinical pharmacokinetics was best described by a one-compartment model with nonlinear absorption and linear elimination. Oxfendazole apparent clearance and apparent volume of distribution were estimated to be 2.57 liters/h and 35.2 liters, respectively, at the lowest dose (0.5 mg/kg), indicating that oxfendazole is a low extraction drug with moderate distribution. The disposition of both metabolites was adequately characterized by a one-compartment model with formation rate-limited elimination. Fenbendazole formation from oxfendazole was primarily through systemic metabolism, while both presystemic and systemic metabolism were critical to the formation of oxfendazole sulfone. Our model adequately captured the concentration-time profiles of both oxfendazole and its two metabolites in healthy adults over a wide dose range. The model can be used to predict oxfendazole disposition under new dosing regimens to support dose optimization in humans.
奥芬达唑是一种强效兽医苯并咪唑驱虫药,正在向人类过渡,用于治疗多种寄生虫感染性疾病。在健康成年人中进行的首次人体研究评估了单剂量递增口服 0.5 至 60mg/kg 体重的奥芬达唑及其代谢物的处置情况,结果表明奥芬达唑药代动力学呈显著非线性,这使得将奥芬达唑剂量与暴露量相关联变得复杂。为了定量捕捉奥芬达唑剂量与暴露量之间的关系,采用非线性混合效应建模方法,建立了奥芬达唑及其代谢物奥芬达唑砜和芬苯达唑在人体中的群体药代动力学模型。我们的最终模型纳入了对剂量限制生物利用度的机制特征描述,以及不同的奥芬达唑代谢过程,并深入了解了奥芬达唑和代谢物处置中预系统代谢的重要性。奥芬达唑临床药代动力学最好通过具有非线性吸收和线性消除的单室模型来描述。在最低剂量(0.5mg/kg)下,奥芬达唑的表观清除率和表观分布容积分别估计为 2.57 升/小时和 35.2 升,表明奥芬达唑是一种低提取药物,具有中等分布。两种代谢物的处置均通过具有形成速率限制消除的单室模型得到充分描述。芬苯达唑由奥芬达唑形成主要通过全身代谢,而全身和预系统代谢对奥芬达唑砜的形成均至关重要。我们的模型充分描述了在广泛剂量范围内健康成年人中奥芬达唑及其两种代谢物的浓度-时间曲线。该模型可用于预测新给药方案下奥芬达唑的处置情况,以支持人类的剂量优化。